NeuroBo Pharmaceuticals – Consensus Indicates Potential 307.8% Upside

Broker Ratings

NeuroBo Pharmaceuticals found using ticker (NRBO) now have 2 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 30 and 20 calculating the mean target price we have 25. Now with the previous closing price of 6.13 this is indicating there is a potential upside of 307.8%. The 50 day MA is 5.5 while the 200 day moving average is 6.64. The market capitalisation for the company is $102m. Visit the company website at: http://www.neurobopharma.com

NeuroBo Pharmaceuticals, a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. Its therapeutics programs include NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. NeuroBo Pharmaceuticals was incorporated in 2017 and is headquartered in Boston, Massachusetts.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit

AIM All Share Index